Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt- chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention. Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months. Results: A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%. Conclusions: In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease.
Abstract
Background/Aims: The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt- chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention. Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months. Results: A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%. Conclusions: In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease.
참고문헌 (19)
- for the Treatment of Up to Two de Novo Coronary Artery Lesions)trial, "J Am Coll Cardiol", 2011, 1700~1708
- El-Hayek G, "Meta-Analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents", JACC Cardiovasc Interv, 10, pp.462~473 (2017)
- Kang SH, "Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents : a systematic review and Bayesian approach network meta-analysis", Eur Heart J, 35, pp.1147~1158 (2014)
- Palmerini T, "Clinical outcomes with bioabsorbable polymer-versus durable polymer-based drug-eluting and bare-metal stents : evidence from a comprehensive network meta-analysis", J Am Coll Cardiol, 63, pp.299~307 (2014)
- Byrne RA, "Coronary balloon angioplasty, stents, and scaffolds", Lancet, 390, pp.781~792 (2017)
- Stefanini GG, "State of the art : coronary artery stents-past, present and future", EuroIntervention, 13, pp.706~716 (2017)
- 양형모, "Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer", Korean Circulation Journal, 47(6), pp.898~906 (2017), 대한심장학회[DOI]
- Seo KW, "Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer", Medicine(Baltimore), 100, pp.e25765~ (2021)
- Young Jin Youn, "Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice", Korean Circulation Journal, 50(4), pp.317~327 (2020), 대한심장학회[DOI]
- Neumann FJ, "2018 ESC", EACTS Guidelines on myocardial revascularization, 2019, pp.40, 87~165
- Valgimigli M, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)", Eur Heart J, 39, pp.213~260 (2018)
- Cutlip DE, "Clinical end points in coronary stent trials: a case for standardized definitions", Circulation, 115, pp.2344~2351 (2007)
- Young-Hyo Lim, "A First-in-Man Clinical Evaluation of Sirolimus and Ascorbic Acid-Eluting Stent Systems: a Multicenter, Subject-Blinded, Randomized Study", Korean Circulation Journal, 51(12), pp.1001~1014 (2021), 대한심장학회[DOI]
- Chang-Hwan Yoon, "Osstem Cardiotec Centum Stent Versus Xience Alpine Stent for De Novo Coronary Artery Lesion: A Multicenter, Randomized, Parallel-Designed, Single Blind Test", Korean Circulation Journal, 52(5), pp.354~364 (2022), 대한심장학회[DOI]
- Bangalore S, "Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease", Circulation, 138, pp.2216~2226 (2018)
- Kobayashi T, "Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents : a systematic review and meta-analysis of 9 randomized controlled trials", Cardiovasc Interv Ther, 35, pp.250~258 (2020)
- Jolly SS, "Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL):a randomised, parallel group, multicentre trial", Lancet, 377, pp.1409~1420 (2011)
- Hyun Kuk Kim, "Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences", Korean Circulation Journal, 51(3), pp.202~221 (2021), 대한심장학회[DOI]
- Yoon CH, "BioMatrix versus Orsiro biodegradable polymer stents in all-comer patients with coronary artery disease: the multicentre, randomised BIODEGRADE trial", EuroIntervention, 16, pp.1404~1412 (2021)